Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

 
• By Sten Stovall
  
Eye
Novartis Licensed Spark's Luxturna Ex-US For Rare Inherited Blindness • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business